Sort by

Send to

Choose Destination

Links from PubMed

Items: 18


Pneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right?

Papadatou I, Spoulou V.

Clin Vaccine Immunol. 2016 May;23(5):388-95. doi: 10.1128/CVI.00721-15. Review.


Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevant.

Musher DM, Rodriguez-Barradas MB.

Hum Vaccin Immunother. 2016;12(2):331-5. doi: 10.1080/21645515.2015.1098794.


Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in Chinese healthy population aged >2 years: A randomized, double-blinded, active control, phase III trial.

Kong Y, Zhang W, Jiang Z, Wang L, Li C, Li Y, Xia J.

Hum Vaccin Immunother. 2015;11(10):2425-33. doi: 10.1080/21645515.2015.1055429.


A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly.

Dirmesropian S, Wood JG, MacIntyre CR, Newall AT.

Hum Vaccin Immunother. 2015;11(4):818-25. doi: 10.1080/21645515.2015.1011954. Review.


Quantitative and Qualitative Antibody Responses to Immunization With the Pneumococcal Polysaccharide Vaccine in HIV-Infected Patients After Initiation of Antiretroviral Treatment: Results From a Randomized Clinical Trial.

Rodriguez-Barradas MC, Serpa JA, Munjal I, Mendoza D, Rueda AM, Mushtaq M, Pirofski LA.

J Infect Dis. 2015 Jun 1;211(11):1703-11. doi: 10.1093/infdis/jiu819.


A randomized clinical trial of the immunogenicity of 7-valent pneumococcal conjugate vaccine compared to 23-valent polysaccharide vaccine in frail, hospitalized elderly.

Macintyre CR, Ridda I, Gao Z, Moa AM, McIntyre PB, Sullivan JS, Jones TR, Hayen A, Lindley RI.

PLoS One. 2014 Apr 23;9(4):e94578. doi: 10.1371/journal.pone.0094578.


Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.

Pichichero ME.

Hum Vaccin Immunother. 2013 Dec;9(12):2505-23. doi: 10.4161/hv.26109. Review.


Pneumococcal vaccine and opsonic pneumococcal antibody.

Song JY, Moseley MA, Burton RL, Nahm MH.

J Infect Chemother. 2013 Jun;19(3):412-25. doi: 10.1007/s10156-013-0601-1. Review.


Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations.

Gupta D, Agarwal R, Aggarwal AN, Singh N, Mishra N, Khilnani GC, Samaria JK, Gaur SN, Jindal SK; Pneumonia Guidelines Working Group..

Lung India. 2012 Jul;29(Suppl 2):S27-62. No abstract available.


Is there a potential role for protein-conjugate pneumococcal vaccine in older adults?

Ridda I, Musher DM.

Australas Med J. 2012;5(4):231-5. doi: 10.4066/AMJ.2012.1160.


Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease.

Dransfield MT, Harnden S, Burton RL, Albert RK, Bailey WC, Casaburi R, Connett J, Cooper JA, Criner GJ, Curtis JL, Han MK, Make B, Marchetti N, Martinez FJ, McEvoy C, Nahm MH, Niewoehner DE, Porszasz J, Reilly J, Scanlon PD, Scharf SM, Sciurba FC, Washko GR, Woodruff PG, Lazarus SC; NIH COPD Clinical Research Network..

Clin Infect Dis. 2012 Sep;55(5):e35-44.


The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia.

Kataoka K, Fujihashi K, Oma K, Fukuyama Y, Hollingshead SK, Sekine S, Kawabata S, Ito HO, Briles DE, Oishi K.

Infect Immun. 2011 Jul;79(7):2819-28. doi: 10.1128/IAI.01360-10.


Adult survivors of invasive pneumococcal disease exhibit defective B cell function.

Darton TC, Wing JB, Lees A, Heath AW, Read RC.

Clin Infect Dis. 2011 May;52(9):1133-6. doi: 10.1093/cid/cir126.


A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults.

Crum-Cianflone NF, Huppler Hullsiek K, Roediger M, Ganesan A, Patel S, Landrum ML, Weintrob A, Agan BK, Medina S, Rahkola J, Hale BR, Janoff EN; Infectious Disease Clinical Research Program HIV Working Group..

J Infect Dis. 2010 Oct 1;202(7):1114-25. doi: 10.1086/656147.


Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease.

Dransfield MT, Nahm MH, Han MK, Harnden S, Criner GJ, Martinez FJ, Scanlon PD, Woodruff PG, Washko GR, Connett JE, Anthonisen NR, Bailey WC; COPD Clinical Research Network..

Am J Respir Crit Care Med. 2009 Sep 15;180(6):499-505. doi: 10.1164/rccm.200903-0488OC.


Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions.

Chapel H, Cunningham-Rundles C.

Br J Haematol. 2009 Jun;145(6):709-27. doi: 10.1111/j.1365-2141.2009.07669.x. Review.

Items per page

Supplemental Content

Support Center